« Zurück
Startseite /
SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein,Biotinylated

SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein,Biotinylated

ArtNr	40592-V08H-B-20
Hersteller	Sino Biological
Menge	20 ug
Kategorie	Infectious Diseases Viral Infections Coronavirus (COVID-19) Peptides & Proteins Recombinant Proteins
Typ	Proteins
Specific against	other
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Lieferbar
Manufacturer - Category	Protein
Purity	> 95 % as determined by SDS-PAGE
Endotoxin	< 1.0 EU per ug protein as determined by the LAL method.
Activity	Testing in progress
Protein Construction	A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro.
Expressed Host	HEK293 Cells
Predicted N Terminal	Arg319
Molecule Mass	The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (RBD, His Tag) consists of 234 amino acids and predicts a molecular mass of 23.54 kDa.
Formulation	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20C to -80C Store it under sterile conditions at -20C to -80C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
References	Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35. Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36. Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 20 ug

lieferbar

Technische Frage stellen